Crucially, pharmacological inhibition of DOT1L enzymatic activity markedly reversed Cd‐induced malignant progression in BC cells (Figure S9, Supporting Information), establishing the functional necessity of DOT1L activity in this pathogenic mechanism. This evidence concerns the gene DOT1L and breast cancer.